

Lighting the way to personalized mRNA immune cell therapies

Ann E. Metzloff¹, Margaret M. Billingsley¹, Michael J. Mitchell^{1,2,3,4,5*}

Nanoparticles, mRNA, and ultraviolet light combine to reprogram specific immune cells directly in the body.

The COVID-19 pandemic has seen the first mRNA vaccines put into global use with administration to billions of people. mRNA vaccines, such as the Pfizer-BioNTech and Moderna COVID-19 vaccines, work by mimicking infection-induced immunity (1). In infection-induced immunity, immune cells—including dendritic cells and T cells—work together to help the body fight infection and disease. The process starts with dendritic cells (DCs), which are scavenger cells that forage for pathogens in the body. When a DC finds a pathogen, it takes up the pathogen, degrades the pathogen, and then displays pieces of the degraded pathogen (called antigens) on its surface via molecules called major histocompatibility complexes (MHCs). The antigen-loaded MHCs act like beacons for T cells, white blood cells that are targeted for one specific antigen. Though each T cell wards off only one type of antigen, the body has billions of T cells, allowing for these immune cells to eliminate almost any antigen. However, the type of MHC on which the antigen is presented determines which subset of T cells are called to action. MHCIs interact with cytotoxic T cells, whereas MHCIIIs interact with helper T cells. After the MHC–T cell interaction, cytotoxic T cells activate to kill cells infected with the pathogens, and helper T cells support the production of pathogen-neutralizing antibodies. In mRNA vaccines, the mRNA is taken up by DCs and translated into antigenic peptide, which is then presented on the DC surface to stimulate T cells as in infection-induced immunity (1). The vaccines encapsulate the mRNA in minuscule fat droplets, called lipid nanoparticles (LNPs), to provide stability in the body and

facilitate delivery into DCs after intramuscular injection (1).

In this issue of *Science Advances*, Su *et al.* (2) explore another promising application of LNP-mRNA therapeutics: direct delivery of mRNA to T cells in the body. Precise targeting of T cells could lead to breakthroughs in the treatment of cancer, infection, and immune disease, but this challenging task is fraught with numerous biological barriers. Using innovative optical techniques, Su *et al.* (2) generated LNPs with the ability to overcome these barriers and deliver mRNA cargo to specific subsets of T cells.

T cell delivery challenges

Delivering therapeutic mRNA to T cells is much more challenging than delivering it to DCs. Many DCs reside in the skin near the site of an intramuscular injection, and—because their job as antigen-presenting cells requires that they forage for pathogens to take up—they readily engulf the injected LNPs. In contrast, most T cells reside in lymphoid tissue, mucosal sites, and human peripheral blood. This means that intravenous administration of mRNA, rather than an intramuscular injection, is required for sufficient T cell delivery. Intravenous administration, unfortunately, presents numerous challenges. One is that intravenously administered LNPs will accumulate in the liver, preventing them from reaching T cells. Even if an LNP does reach a T cell, the T cell will not take up the LNP as readily as a DC would because foraging is not part of a T cell's job.

To overcome these issues, researchers are creating nanoparticles with surface modifications, such as antibody fragments, that

allow specific binding to T cells. By attaching T cell-specific antibody fragments to the nanoparticle surface, researchers have engineered targeted nanoparticles for T cell delivery (3, 4). When tested, these targeted nanoparticles can efficiently deliver mRNA cargo to T cells (4). Particles such as these—that broadly target all T cells regardless of antigen specificity—would be useful to mediate a strong, total T cell response for applications in cancer therapy.

When treating certain viral infections or virus-mediated cancers, however, it is often desirable to target only T cells that are specific to the disease instead of all T cells. Enhancing only disease-specific T cells would help the immune system to maintain self-tolerance and avoid inflammation resulting from overactivity (2). Toward this goal, researchers have worked to develop nanoparticles that have antigenic peptide-MHCI (pMHCI) complexes conjugated to their surfaces (5–7). Mimicking DC–T cell interactions, particles engineered in this manner can only interact with the cytotoxic T cells that are specific to the chosen antigenic peptides. The research published to date has focused mainly on activating disease-specific T cells.

Using light to create targeted LNP technology

Su *et al.* (2) attached pMHCI molecules to LNPs for the delivery of mRNA to disease-specific T cells—with the goal of reprogramming the cells instead of only activating them. This is valuable because T cells can be reprogrammed with mRNA to make new proteins, such as therapeutic receptors or stimulatory proteins.

Su *et al.* (2) first created the LNPs—the minuscule fat droplets—by combining a fat mixture with mRNA in a microfluidic mixing channel. Then, they worked to synthesize and incorporate the disease-specific pMHCI. Historically, researchers synthesized pMHCI molecules in a complicated, stepwise process,

Copyright © 2022
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim to
original U.S. Government
Works. Distributed
under a Creative
Commons Attribution
NonCommercial
License 4.0 (CC BY-NC).

¹Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA. ²Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA. ³Institute for Immunology, University of Pennsylvania, Philadelphia, PA 19104, USA. ⁴Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA 19104, USA. ⁵Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

*Corresponding author. Email: mjmitch@seas.upenn.edu




Fig. 1. Ultraviolet light generates a library of peptide-MHC1 molecules, which are then inserted into lipid nanoparticles to create antigen-presenting nanoparticles. These nanoparticles deliver mRNA to specific groups of T cells (2). This technology could help make new treatments for certain cancers and viruses a reality. Credit: Ashley Mastin/Science Advances.

which rendered generating large libraries of pMHCs prohibitively time-consuming (8). Fortunately, strategies to efficiently swap different peptides into pMHCs have recently been developed, such as ultraviolet (UV) light-mediated peptide exchange (8). Using this strategy, Su *et al.* (2) synthesized the MHCs with a placeholder peptide. The placeholder peptide degrades when exposed to UV light, exposing the MHC1 presentation groove and allowing a new antigenic peptide to bind (8). This means that a single batch of placeholder-MHCI can be synthesized and exposed to UV light, and then multiple antigenic peptides can be added at once to generate a library of pMHC1 molecules in one step. Su *et al.* (2) conjugated their UV-exchanged pMHC1 molecules to fat molecules, which acted like tethers to secure the pMHCs to the surface of their mRNA-containing LNPs to create antigen-presenting nanoparticles (APNs) (Fig. 1).

Targeted LNP validation in mice

Su *et al.* (2) first compared their UV-exchanged pMHC1 APNs with conventionally refolded (the long, stepwise process) pMHC1 APNs in three mouse models and found that both APNs successfully targeted and delivered their

cargo mRNA to antigen-specific cytotoxic T cells. This shows that their new, easier to produce, UV-exchanged pMHCs work just as well as conventionally refolded pMHCs to target specific groups of cytotoxic T cells. Second, Su *et al.* (2) gave mice an intravenous injection of a mixture of three types of UV-exchanged APNs, each carrying a different influenza A antigenic peptide. They observed mRNA delivery to the three antigen-specific cytotoxic T cell populations at significantly higher rates compared to other cell populations, demonstrating that these APNs can target multiple cytotoxic T cell populations simultaneously.

Impact and future directions

This approach improves the precision with which mRNA-containing LNPs can target and deliver their cargo to specific cytotoxic T cell populations and can be efficiently scaled to generate large libraries of APNs. In their study, Su *et al.* (2) lay the groundwork for applications in influenza, but their APNs could also be adapted for cancer immunotherapy by using pMHCs with tumor antigens to target cancer-specific cytotoxic T cells. However, this study only considers the functionalization of LNPs with pMHCs

for engineering cytotoxic T cells. Perhaps LNPs could similarly be functionalized with pMHCs for engineering helper T cells, which might have important therapeutic applications for the treatment of autoimmune diseases or the malignant tumor microenvironment. Furthermore, some immunotherapies are most effective when both cytotoxic and helper T cells participate (9), so the ability to target both cell types via a mixture of pMHC1 and pMHC2 APNs could prove beneficial. However, Su *et al.* (2) hypothesize that the generation of pMHC2 APNs may be more difficult than the production of pMHC1 APNs since MHC2s interact more weakly with both peptides and T cells than do MHC1s. Nevertheless, pMHC1 APN technology (2) is an exciting step toward illuminating the goal of creating personalized immune cell therapies and vaccines.

REFERENCES

1. N. Chaudhary, D. Weissman, K. A. Whitehead, mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. *Nat. Rev. Drug Discov.* **20**, 817–838 (2021).
2. F.-Y. Su, Q. Zhao, S. N. Dahotre, L. Gamboa, S. S. Bawage, A. D. Silva Trenkle, A. Zamat, H. Phuengkham, R. Ahmed, P. J. Santangelo, G. A. Kwong, *In vivo* mRNA delivery to virus-specific T cells by light-induced ligand exchange

- of MHC class I antigen-presenting nanoparticles. *Sci. Adv.* **8**, eabm7950 (2022).
3. T. T. Smith, S. B. Stephan, H. F. Moffett, L. E. McKnight, W. Ji, D. Reiman, E. Bonagofski, M. E. Wohlfahrt, S. P. S. Pillai, M. T. Stephan, In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. *Nat. Nanotech.* **12**, 813–820 (2017).
 4. N. N. Parayath, S. B. Stephan, A. L. Koehne, P. S. Nelson, M. T. Stephan, In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. *Nat. Commun.* **11**, 6080 (2020).
 5. L. Zhang, S. Song, X. Jin, X. Wan, K. A. Shahzad, W. Pei, C. Zhao, C. Shen, An artificial antigen-presenting cell delivering 11 immune molecules expands tumor antigen-specific CTLs in ex vivo and in vivo murine melanoma models. *Cancer Immunol. Res.* **7**, 1188–1201 (2019).
 6. X. Zhang, M. Luo, S. R. Dastagir, M. Nixon, A. Khamhoung, A. Schmidt, A. Lee, N. Subbiah, D. C. McLaughlin, C. L. Moore, M. Gribble, N. Bayhi, V. Amin, R. Pepi, S. Pawar, T. J. Lyford, V. Soman, J. Mellen, C. L. Carpenter, L. A. Turka, T. J. Wickham, T. F. Chen, Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic. *Nat. Commun.* **12**, 2637 (2021).
 7. S. Ugel, A. Zoso, C. deSanto, Y. Li, I. Marigo, P. Zanovello, E. Scarselli, B. Cipriani, M. Oelke, J. P. Schneck, V. Bronte, In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. *Cancer Res.* **69**, 9376–9384 (2009).
 8. B. Rodenko, M. Toebes, S. R. Hadrup, W. J. E. van Esch, A. M. Molenaar, T. N. M. Schumacher, H. Ovaa, Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. *Nat. Protoc.* **1**, 1120–1132 (2006).
 9. D. Sommermeyer, M. Hudecek, P. L. Kosasih, T. Gogishvili, D. G. Maloney, C. J. Turtle, S. R. Riddell, Chimeric antigen receptor-modified T cells derived from defined CD8⁺ and CD4⁺ subsets confer superior antitumor reactivity *in vivo*. *Leukemia* **30**, 492–500 (2016).

10.1126/sciadv.abo2423

Lighting the way to personalized mRNA immune cell therapies

Ann E. MetzloffMargaret M. BillingsleyMichael J. Mitchell

Sci. Adv., 8 (8), eabo2423. • DOI: 10.1126/sciadv.abo2423

View the article online

<https://www.science.org/doi/10.1126/sciadv.abo2423>

Permissions

<https://www.science.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of service](#)

Science Advances (ISSN) is published by the American Association for the Advancement of Science. 1200 New York Avenue NW, Washington, DC 20005. The title *Science Advances* is a registered trademark of AAAS.
Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).